Topical retinoid therapy is a long-established course of treatment in dermatology, most widely known for its effectiveness in managing skin ageing and acne. However, mild to moderate cutaneous side effects due to topical retinoid use, such as peeling, erythema and subjective irritation, which are related to skin barrier disruption, are experienced by a majority of patients seen by physicians in their practices.
The goal at SkinCeuticals has been to research ways in which we could offer a support system to our physicians, whereby they could prescribe retinoids to their tretinoin sensitive or first time patients. A new clinical study began in late 2016 with the results being published this year, in order to identify ways to improve skin tolerability and achieve the benefits of a topical retinoid without the associated skin dryness.
Over the course of a 4-week study, SkinCeuticals’ Triple Lipid Restore 2:4:2 and a comparative lotion were applied to the face of 17 patients in a split-face, randomized manner. Subjects were instructed to apply topical 0.025% tretinoin to their whole face at home every other evening for 1 week. Based on the subjects’ tolerability, topical 0.025% tretinoin application was increased to every evening at the week 1 or week 2 visit. The purpose of this study was to evaluate the potential of Triple Lipid Restore 2:4:2 to improving the tolerance of 0.025% topical tretinoin therapy.
In order to minimise the adverse effects related to retinoid therapy for patients, it is generally recommended that a retinoid treatment regimen consist of application on alternate nights for the first 2 weeks of use, at minimum, or until deemed tolerable. Triple Lipid Restore 2:4:2 allowed for all 17 subjects to achieve a 1 week decrease in 0.025% tretinoin pre-conditioning, shortening the current standard treatment of care by 1 week.
Triple Lipid Restore 2:4:2 significantly improved dryness at week 2, as measured by clinical grading and was reported to be significantly more comfortable than a comparative lotion.